1. Type 2 Innate Lymphoid Cells Protect against Colorectal Cancer Progression and Predict Improved Patient Survival
- Author
-
Melissa J. Davis, Philip M. Hansbro, Gabrielle T. Belz, Nicolas Jacquelot, Tracy L Putoczki, Fernando Souza-Fonseca-Guimaraes, Qiutong Huang, Adele Preaudet, Andrew N. J. McKenzie, Soroor Hediyeh-Zadeh, Lisa A. Mielke, Jacquelot, Nicolas [0000-0003-0282-1892], Souza-Fonseca-Guimaraes, Fernando [0000-0002-2037-8946], Mielke, Lisa A [0000-0002-9522-9320], Putoczki, Tracy L [0000-0003-1639-4932], and Apollo - University of Cambridge Repository
- Subjects
0301 basic medicine ,Cancer Research ,Colorectal cancer ,Inflammation ,lcsh:RC254-282 ,Article ,ILC2 ,03 medical and health sciences ,0302 clinical medicine ,Immunity ,medicine ,IL-5 ,Innate immune system ,business.industry ,Innate lymphoid cell ,Cancer ,Gene signature ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,digestive system diseases ,030104 developmental biology ,Oncology ,colon cancer ,inflammation ,030220 oncology & carcinogenesis ,IL-13 ,Interleukin 13 ,colitis-associated cancer ,Cancer research ,medicine.symptom ,business - Abstract
Simple Summary Colorectal cancer is the second leading cause of cancer-related death worldwide. The immune system plays a key role in controlling tumour onset and development. However, our immune system is complex and includes many different cell types which differently impact colorectal cancer outcomes. In this study, we investigated the function of the specialised type 2 innate lymphoid cells (ILC2) in colorectal cancer development and progression. We found that ILC2 infiltrate colorectal tumours and their presence was associated with reduced tumour burden in mice. In patients, this infiltration correlated with improved overall survival. Collectively, our work reveals that ILC2s are beneficial to colorectal cancer outcomes. Abstract Chronic inflammation of the gastrointestinal (GI) tract contributes to colorectal cancer (CRC) progression. While the role of adaptive T cells in CRC is now well established, the role of innate immune cells, specifically innate lymphoid cells (ILCs), is not well understood. To define the role of ILCs in CRC we employed complementary heterotopic and chemically-induced CRC mouse models. We discovered that ILCs were abundant in CRC tumours and contributed to anti-tumour immunity. We focused on ILC2 and showed that ILC2-deficient mice developed a higher tumour burden compared with littermate wild-type controls. We generated an ILC2 gene signature and using machine learning models revealed that CRC patients with a high intratumor ILC2 gene signature had a favourable clinical prognosis. Collectively, our results highlight a critical role for ILC2 in CRC, suggesting a potential new avenue to improve clinical outcomes through ILC2-agonist based therapeutic approaches.
- Published
- 2021